To include your compound in the COVID-19 Resource Center, submit it here.

Verastem gains on duvelisib Priority Review

Verastem Inc. (NASDAQ:VSTM) added $0.32 (11%) to $3.22 on Monday after it said FDA accepted and granted Priority Review to an NDA seeking full

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE